CN114291821B - PH-responsive copper silicate nanoparticle for enhancing curcumin anti-tumor curative effect and preparation and application thereof - Google Patents
PH-responsive copper silicate nanoparticle for enhancing curcumin anti-tumor curative effect and preparation and application thereof Download PDFInfo
- Publication number
- CN114291821B CN114291821B CN202210006050.5A CN202210006050A CN114291821B CN 114291821 B CN114291821 B CN 114291821B CN 202210006050 A CN202210006050 A CN 202210006050A CN 114291821 B CN114291821 B CN 114291821B
- Authority
- CN
- China
- Prior art keywords
- copper
- curcumin
- solution
- copper silicate
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a pH response type copper silicate nanoparticle for enhancing curcumin anti-tumor curative effect and preparation and application thereof. Antineoplastic CuSiO 3 /CUR comprising the cross-linking of DSPE-PEG-NH by distearoylphosphatidylethanolamine-polyethylene glycol-amino 2 Modified curcumin and copper silicate nanoparticles. The copper silicate nano-particles adopted by the invention are used as inorganic nano-particle drug carriers, and due to the hollow sea urchin-shaped appearance characteristics, the drug loading capacity is better, and the drug loading capacity is kept stable for a long time. The copper silicate nano-particles can be gathered in tumors through an EPR effect, so that Cu in the tumors is increased 2+ Content of Cu 2+ Can generate free Radicals (ROS) in cooperation with curcumin in a tumor area.
Description
Technical Field
The invention belongs to the field of nano biomedicine, and relates to preparation and application of pH response type copper silicate nanoparticles capable of enhancing the anti-tumor curative effect of curcumin.
Background
Curcumin is an anti-inflammatory molecule that reacts with many molecules recruited by inflammatory signaling pathways, thereby inhibiting tumor initiation and progression. But the dispersibility of the compound in physiological environment is low, so that the anti-tumor curative effect of the compound is limited. It has been shown that curcumin is associated with copper ions (Cu) 2+ ) Can generate singlet oxygen after combination 1 O 2 ) Thereby inhibiting the activity of related protease of tumor cells and enhancing the anti-tumor capability. Thus, cu 2+ The existence of the curcumin is one of the key factors for improving the anti-tumor effect of the curcumin. However, 1 O 2 depends on oxygen (O) in the environment 2 ). The characteristics of hypoxic tumor environment are influence 1 O 2 Creating a large obstruction. How to increase O in tumors 2 The content is another key for realizing the high-efficiency tumor inhibition of the curcumin.
Disclosure of Invention
The invention aims at improving the anti-tumor curative effect of curcumin and provides a preparation method of pH response type copper silicate nanoparticles, which increases the active sites of copper elements on the nanoparticles, promotes the synergistic effect of copper ions and curcumin and improves the anti-tumor curative effect of curcumin.
The invention relates to a preparation method of pH response type copper silicate nano particles, which adopts a hydrothermal method to prepare and specifically comprises the following steps:
dissolving a surfactant and ammonium fluoride in a deionized water mixed solution, adding tetraethoxysilane after magnetic stirring for 1-2 hours, magnetically stirring for 3-5 hours, and performing centrifugal separation to obtain mesoporous silica particles;
the silicon dioxide microspheres in the step 1 are prepared according to a stober method, and the particle size of the silicon dioxide microspheres is 80-120nm.
Dispersing the mesoporous silica particles obtained in the step (1) in deionized water to form a white emulsion A; dissolving a copper-containing compound and disodium maleate in deionized water to obtain a solution B;
and (3) mixing the emulsion A and the solution B formed in the step (2) under stirring to form an emulsion C, placing the emulsion C in a reaction kettle, and reacting for a certain time at a high temperature.
Preferably, the surfactant in step 1 is at least one of cetyltrimethylammonium bromide, cetyltrimethylammonium chloride, cetyltriethylammonium bromide, trioctylmethylammonium chloride and dodecyltrimethylammonium chloride, and is preferably cetyltrimethylammonium bromide.
Preferably, the molar ratio of the surfactant, ammonium fluoride, ethyl orthosilicate and water in step 1 is 0.19:3.2:1.776: (800-1200).
Preferably, the mesoporous silica concentration in white emulsion A in step 2 is from 0.5mg/ml to 2mg/ml.
Preferably, the copper-containing compound in step 2 is copper acetate, copper chloride, copper nitrate or copper sulfate.
Preferably, the hydrothermal reaction temperature in the step 3 is 120-160 ℃, and the reaction time is 5-15h.
Preferably, the mass ratio of the copper-containing compound to the mesoporous silica in step 3 is 1:1-2.
The second purpose of the invention is to provide copper silicate nano particles prepared by the method. The copper silicate nano particles are hollow sea urchin-shaped structures, and the size of the copper silicate nano particles is 150-200nm; the copper is uniformly distributed throughout the nanoparticles.
The third purpose of the invention is to provide the application of the copper silicate nano particles as curcumin carriers.
Preferably, the copper silicate nanoparticles are dispersed in an ethanol solution to form a solution A; dissolving curcumin and polyethylene glycol (PEG) in ethanol to form a solution B; and mixing the solution A and the solution B, and stirring for a period of time to obtain the curcumin-loaded copper silicate nanoparticles.
Preferably, the mass ratio of curcumin to PEG in the solution B is (1.
Preferably, the mass ratio of the copper silicate nanoparticles to the curcumin is (1.
Preferably, the stirring time after mixing the solution A and the solution B is 4 to 12 hours.
The fourth purpose of the invention is to provide an antitumor drug CuSiO 3 /CUR comprising the cross-linking of DSPE-PEG-NH by distearoylphosphatidylethanolamine-polyethylene glycol-amino 2 Modified curcumin and copper silicate nanoparticles.
The proportion of the copper silicate nanoparticles to the curcumin drug in the nano drug delivery system can be adjusted according to the types of tumor cells.
Furthermore, the dosage ratio of the copper silicate nano particles to the curcumin is satisfied, so that the copper silicate nano particles smoothly enter a body by an injection mode and reach a specific tumor part, and the enrichment of the tumor part is maximum.
The copper silicate nano-particles provided by the invention have sea urchin-shaped appearance characteristics, so that the specific surface area is larger, and the drug loading rate is also larger. The copper silicate nano particles have a large number of copper element active sites, and can better perform a synergistic reaction after copper ions and curcumin are released, so that the treatment effect is improved.
The fifth purpose of the invention is to provide a drug delivery system for the antitumor drug CuSiO 3 the/CUR is dispersed in any physiological saline or buffered salt suitable for clinical use and administered to the body as an injection.
Preferably, the normal saline is a sodium chloride solution with the mass fraction of 0.9%.
Preferably, the buffer salt is PBS buffer of pH = 7-9.
In a tumor region with high hydrogen peroxide expression, the copper silicate nanoparticles are degraded to obtain copper ions, and the copper ions and curcumin cooperate to generate free Radicals (ROS) to generate a certain anti-tumor effect. Because curcumin and copper ions are released in situ in tumors, the tumor selective treatment can be realized by taking the copper silicate nanoparticles as curcumin carriers. The tumor includes but is not limited to ovarian cancer, breast cancer, lung cancer, liver cancer or brain cancer, etc.
The invention has the following advantages:
1) The copper silicate nano-particles adopted by the invention are used as inorganic nano-particle drug carriers, and due to the hollow sea urchin-shaped appearance characteristics, the drug loading capacity is better, and the drug loading capacity is kept stable for a long time.
2) CuSiO of the invention 3 The CUR nano drug delivery system can deliver curcumin drugs to tumor parts, improves the curative effect of chemotherapeutic drugs, and provides a new idea for tumor selective treatment aiming at tumor cells.
3) The copper silicate nano-particles can be gathered in tumors through an EPR effect, so that Cu in the tumors is increased 2+ Content of Cu 2+ Can generate free Radicals (ROS) in cooperation with curcumin in a tumor area.
4) The nano material provided by the invention can be used as a curcumin carrier to be released in a tumor weak acid microenvironment regioselectively and generate a Cu-CUR complex, so that the potential biological toxicity of a medicament to normal tissues is overcome.
5) The copper silicate nano material provided by the invention has more active sites of copper elements, and can more easily act between copper ions and curcumin in a tumor region, so that the treatment effect is improved.
6) The copper silicate nano-particles adopted by the invention obtain good tumor cell killing effect after loading curcumin, and meanwhile, the weight of organisms is not reduced.
Drawings
FIG. 1 is a TEM image of copper silicate nanoparticles;
FIG. 2 is the EDS element distribution of Si, O and Cu elements in copper silicate nanoparticles;
FIG. 3 is a graph of copper ion release curves for copper silicate nanoparticles under different acidic conditions;
FIG. 4 shows the cell viability of 4T1 cells after treatment by different methods;
FIG. 5 shows the cell viability of L929 cells after treatment by different methods;
FIG. 6 shows the curves of the change in tumor volume of mice after different treatments, error bars being the standard deviation of the tumor volume ratio of 5 mice;
FIG. 7 shows the body weight curves of mice after different treatments, with error bars being the standard deviation of body weight of 5 mice.
Detailed Description
The invention will be further described with reference to specific examples, but the scope of the invention is not limited thereto. It is noted that the following processes, if not specifically described in detail, are all realizable or understandable by those skilled in the art with reference to the prior art. The reagents or apparatus used are not indicated to the manufacturer and are considered to be conventional products available by commercial purchase.
As described above, in view of the deficiencies of the prior art, the present inventors have made extensive studies and extensive practices, and propose a technical solution of the present invention, which is mainly based on at least: (1) The copper silicate nano-particles have sea urchin-shaped morphology characteristics, so that the specific surface area is larger, a large number of copper element active sites exist, and the drug loading rate is larger. (2) The copper silicate nano-particles have certain catalase activity, and can catalyze H within a certain time under physiological conditions 2 O 2 To generate a certain amount of O 2 The composite can improve the hypoxic of the tumor part to a certain extent, and can better perform a synergistic reaction after releasing copper ions and curcumin, thereby increasing the treatment effect. (3) The copper silicate nano-particles can be degraded under physiological conditions, slowly degrade under the neutral pH condition of normal tissues, and can be rapidly degraded to generate copper ions at tumor sites with low pH, so that the copper silicate nano-particles have better biological safety. (4) CuSiO 3 the/CUR nano-particles have high selective tumor toxicity, can deliver curcumin drugs to tumor parts through an EPR effect, improve tumor enrichment of chemotherapeutic drugs, reduce systemic toxic and side effects caused by the traditional administration route, and play a certain role in promoting tumor treatment. (5) After the copper silicate nanoparticles are used as curcumin carriers to release curcumin and copper ions at tumor sites, the curcumin carriers can synergistically improve the level of free Radicals (ROS) in tumor cells and inhibit the activity of related proteasomes, so that the apoptosis of the tumor cells is specifically induced. Such proteases include, but are not limited to, superoxide dismutase, peroxidase, catalase, serine proteases, and the like.
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention. In addition, the technical features involved in the embodiments of the present invention described below may be combined with each other as long as they do not conflict with each other.
A preparation method of pH response type copper silicate nano-particles adopts a hydrothermal method to prepare the copper silicate nano-particles. The preparation method comprises the following steps:
dissolving a surfactant and ammonium fluoride in a deionized water mixed solution, adding tetraethoxysilane after magnetic stirring for 1-2 hours, magnetically stirring for 3-5 hours, and performing centrifugal separation to obtain mesoporous silica particles;
the silicon dioxide microspheres in the step 1 are prepared according to a stober method, and the particle size of the silicon dioxide microspheres is 80-120nm.
Dispersing the mesoporous silica particles obtained in the step (1) in deionized water to form a white emulsion A; dissolving a copper-containing compound and disodium maleate in deionized water to obtain a solution B;
and (3) mixing the emulsion A formed in the step (2) with the solution B while stirring to form an emulsion C, placing the emulsion C into a reaction kettle, and reacting for a certain time at a high temperature.
Preferably, the surfactant in step 1 is at least one of cetyltrimethylammonium bromide, cetyltrimethylammonium chloride, cetyltriethylammonium bromide, trioctylmethylammonium chloride and dodecyltrimethylammonium chloride, and is preferably cetyltrimethylammonium bromide.
Preferably, the molar ratio of the surfactant, ammonium fluoride, ethyl orthosilicate and water in step 1 is 0.19:3.2:1.776: (800-1200).
Preferably, the mesoporous silica concentration in white emulsion A in step 2 is from 0.5mg/ml to 2mg/ml.
Preferably, the copper-containing compound in step 2 is copper acetate, copper chloride, copper nitrate or copper sulfate.
Preferably, the hydrothermal reaction temperature in the step 3 is 120-160 ℃, and the reaction time is 5-15h.
Preferably, the mass ratio of the copper-containing compound to the mesoporous silica in the step 3 is 1:1-2.
Provides a copper silicate nanoparticle prepared by the method. The copper silicate nano particles are hollow sea urchin-shaped structures, and the size of the copper silicate nano particles is 150-200nm; the copper is uniformly distributed throughout the nanoparticles.
The application of the copper silicate nanoparticles as curcumin carriers is provided, and the steps of loading curcumin are as follows: dispersing the copper silicate nano particles in an ethanol solution to form a solution A; dissolving curcumin and polyethylene glycol (PEG) in ethanol to form a solution B; and mixing the solution A and the solution B, and stirring for a period of time to obtain the curcumin-loaded copper silicate nanoparticles.
Preferably, the mass ratio of the curcumin to the PEG in the solution B is 1: 1.
preferably, the mass ratio of the copper silicate nanoparticles to the curcumin is 1:8.
preferably, the stirring time after mixing the solution A and the solution B is 4 to 12 hours.
Provides the application of the copper silicate nano particles as curcumin carriers.
Provides an antitumor drug, which comprises distearoyl phosphatidyl ethanolamine-polyethylene glycol-amino cross-linked drug DSPE-PEG-NH 2 Modified curcumin and copper silicate nanoparticles.
Provides a drug delivery system, which disperses the anti-tumor drug in any normal saline or buffer salt suitable for clinical application and is applied to the body in the form of injection.
Preferably, the normal saline is a sodium chloride solution with the mass fraction of 0.9%.
Preferably, the buffer salt is PBS buffer of pH = 7-9.
The technical solutions of the present invention are further explained below with reference to some preferred embodiments, but the experimental conditions and the setting parameters should not be construed as limitations of the basic technical solutions of the present invention. And the scope of the present invention is not limited to the following examples.
Example 1
1. Preparation of mesoporous silica
Cetyl trimethylammonium bromide (0.18 g) and ammonium fluoride (0.3 g) were first dissolved in 45ml of deionized water, and after magnetic stirring at 80 ℃ for 1 hour, a mixed solution of tetraethoxysilane (1 ml) and ethanol (4 ml) was slowly added dropwise to the above solution, after magnetic stirring at 80 ℃ for 4 hours, the synthesized nanospheres were collected by centrifugation (9000 rpm,5 minutes) and washed three times with ethanol, and after freeze-drying the product for 48 hours, mesoporous silica nanospheres having a size of about 80-120nm were obtained.
2. Preparation of hollow copper silicate nanoparticles
Adding the mesoporous silicon dioxide (10 mg) obtained in the step 1 into 10ml of deionized water, and performing ultrasonic dispersion to form white emulsion; copper acetate (10 mg) and disodium maleate (100 mg) were dissolved in 10ml of deionized water, and the two solutions were mixed well and stirred with ultrasound for 30 minutes. Transferring the mixed emulsion into a stainless steel autoclave with polytetrafluoroethylene as an inner lining, preserving the heat for 12h at 140 ℃, cooling to room temperature, centrifuging (9000rpm, 5 min), washing for 3 times by using deionized water to obtain a product CuSiO 3 . FIG. 1 shows CuSiO 3 The TEM image of the copper silicate nanoparticles shows that the particle size distribution of the copper silicate nanoparticles is uniform, and the copper silicate nanoparticles have a hollow sea urchin-like structure and are about 150-200nm; figure 2 is the EDS elemental distribution of Cu, si and O in copper silicate, indicating that copper is uniformly distributed throughout the nanoparticle and that there are a large number of copper active sites.
Example 2 preparation of curcumin-loaded hollow copper silicate nanoparticles
8 mg of the prepared copper silicate nanoparticles were added to ethanol (5 ml) and sonicated for 10 minutes to form a uniform dispersion. Then, 2mg curcumin and 1 mg distearoylphosphatidylethanolamine-polyethylene glycol-amino cross-linker DSPE-PEG-NH were added 2 Add to ethanol (5 ml), mix the two solutions well and stir magnetically at room temperature for 6 hours. After centrifugation (9000rpm, 5 minutes), the obtained product is washed with ethanol and water for three times to obtain CuSiO 3 (iii)/CUR nanoparticles.
Example 3, hollow copper silicate nanoparticles prepared in example 1 released copper ions at different pH:
1mL of copper ion with a concentration of 2 mg. ML -1 The copper silicate solution of (2) is sealed in dialysis bags (MCWO: 1000 Da) and immersed in centrifuge tubes containing 20mL of buffer media of different pH (pH =7.4,6.5 and 5.4). The centrifuge tube was shaken at 200 rpm and, at given intervals, 1mL of the buffer was taken out and 1mL of fresh buffer was returned, and the copper ion concentration in the taken-out 1mL of buffer was analyzed by ICP-AES. FIG. 3 is a graph showing the release of copper ions from copper silicate particles under different acidic conditions, and it can be seen that the copper silicate particles exhibit a pH-dependent release capacity of copper ions, and 93% of Cu can be released from the copper silicate particles within 24 hours under the acidic buffer condition at pH5.4 2+ While in neutral buffer solution of pH7.4, only 52% of Cu is present 2+ And releasing. Under acidic buffer, the copper silicate nanoparticles release Cu 2+ Is faster than neutral buffer and can better aggregate at the tumor site.
Examples 4,
CUR, preparation of example 1 to obtain CuSiO 3 Example 2 preparation of CuSiO 3 Cytotoxicity of CUR on mouse breast cancer cells (4T 1) and mouse fibroblasts (L929): mixing the above two cells at 5 × 10 3 Density of individual/well in 96-well plates, at 5% CO 2 Cells were allowed to adhere by incubation overnight in a 37 ℃ incubator. Then adding the CUR and CuSiO with gradient concentration 3 、CuSiO 3 (ii)/CUR. After further incubation for 24 hours, cell viability was determined using the MTT method, fig. 4 is a study of cell viability of 4T1 cells, and fig. 5 is a study of cell viability of L929 cells. As can be seen, cuSiO 3 the/CUR can inhibit the proliferation of 4T1 cells in a dose-dependent manner, and is used in the fields of CUR and CuSiO 3 、CuSiO 3 In the/CUR, the effect after drug loading is the best. At the same dosage, CUR and CuSiO 3 、CuSiO 3 the/CUR has little damage to normal cells, which indicates that CuSiO 3 The pH responsiveness of the/CUR promotes the release of copper ions in the tumor, and the copper ions and the curcumin are complexed to cause certain damage to tumor cells and simultaneously cause less damage to normal cells.
Example 4, example2 preparation to obtain CuSiO 3 In vivo tumor suppression of CUR
Female Balb/c mice with an average weight of 20 g and 20 mice for 6 weeks were injected subcutaneously into the right hind leg for 1-10 days 6 4T1 cells, each inoculated with 0.1ml of cell suspension (dispersed in PBS), when the tumor volume reached 80-120mm 3 On the left and right, 20 mice were randomly divided into 4 groups: (1) mice were intratumorally injected with physiological saline only as a control group; (2) Injecting normal saline and CUR into mouse tumor, the curcumin injection amount is 6.5 mg.Kg -1 . (ii) a (3) Mice are injected with normal saline in tumor and CuSiO is prepared in example 1 3 The injection amount of the copper silicate nano particles is 25 mg-Kg -1 (ii) a (4) Mice are injected with normal saline in tumor and CuSiO is prepared in example 2 3 /CUR, wherein CuSiO 3 Curcumin injection amount in CUR is 6.5 mg.Kg -1 . . All of the CUR groups, cuSiO 3 Group or CuSiO 3 the/CUR group had equivalent CUR doses and had equivalent particle doses. All groups were injected every two days for 10 days and tumor volume and mouse body weight were monitored 1 day after injection. CuSiO as shown in FIG. 6 3 The tumor volume of the CUR group is obviously reduced, which indicates that CuSiO 3 the/CUR can achieve certain effect on tumor treatment not only on cell level but also on animal tissue level. FIG. 7 shows the body weight curves of mice after different treatments, with error bars being the standard deviation of body weight of 5 mice.
The above embodiments are not intended to limit the present invention, and the present invention is not limited to the above embodiments, and all embodiments are within the scope of the present invention as long as they meet the requirements of the present invention.
Claims (9)
1. A preparation method of pH response type copper silicate nano-particles is characterized by comprising the following steps:
dissolving a surfactant and ammonium fluoride in a deionized water mixed solution, adding tetraethoxysilane after magnetic stirring for 1-2 hours, magnetically stirring for 3-5 hours, and performing centrifugal separation to obtain mesoporous silica particles with the particle size of 80-120 nm;
dispersing the mesoporous silica particles obtained in the step (1) in deionized water to form a white emulsion A; dissolving a copper-containing compound and disodium maleate in deionized water to obtain a solution B;
step (3), mixing the emulsion A formed in the step (2) with the solution B while stirring to form emulsion C, placing the emulsion C in a reaction kettle, and reacting for a certain time at a high temperature; the mass ratio of the copper-containing compound to the mesoporous silica is 1:1-2.
2. The method of claim 1, wherein the surfactant in step 1 is at least one of cetyltrimethylammonium bromide, cetyltrimethylammonium chloride, cetyltriethylammonium bromide, trioctylmethylammonium chloride, dodecyltrimethylammonium chloride; the copper-containing compound is copper acetate, copper chloride, copper nitrate or copper sulfate; the molar ratio of the surfactant to the ammonium fluoride to the ethyl orthosilicate to the water is 0.19:3.2:1.776: (800-1200).
3. The method of claim 1, wherein the mesoporous silica concentration in white emulsion a in step 2 is from 0.5mg/ml to 2mg/ml.
4. The method according to claim 1, wherein the hydrothermal reaction temperature in step 3 is 120-160 ℃ and the reaction time is 5-15 hours.
5. Use of a copper silicate nanoparticle prepared by the method of any one of claims 1-4 as a curcumin carrier.
6. The use according to claim 5, characterized in that the copper silicate nanoparticles are dispersed in an ethanol solution to form a solution A; dissolving curcumin and polyethylene glycol (PEG) in ethanol to form a solution B; and mixing the solution A and the solution B, and stirring for a period of time to obtain the curcumin-loaded copper silicate nanoparticles.
7. The use as claimed in claim 6, wherein the ratio of curcumin to PEG in the B solution is (1; the mass ratio of the copper silicate nanoparticles to the curcumin is (1; the stirring time after the solution A and the solution B are mixed is 4-12h.
8. Antitumor drug CuSiO 3 /CUR, characterized in that it comprises a DSPE-PEG-NH cross-linked by distearoylphosphatidylethanolamine-polyethylene glycol-amino group 2 Modified curcumin and a copper silicate nanoparticle prepared by the method of any one of claims 1 to 4.
9. A drug delivery device characterized in that the antitumor drug CuSiO of claim 8 is applied to a patient 3 the/CUR is dispersed in any physiological saline or buffered salt suitable for clinical use and administered to the body as an injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210006050.5A CN114291821B (en) | 2022-01-05 | 2022-01-05 | PH-responsive copper silicate nanoparticle for enhancing curcumin anti-tumor curative effect and preparation and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210006050.5A CN114291821B (en) | 2022-01-05 | 2022-01-05 | PH-responsive copper silicate nanoparticle for enhancing curcumin anti-tumor curative effect and preparation and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114291821A CN114291821A (en) | 2022-04-08 |
| CN114291821B true CN114291821B (en) | 2023-03-07 |
Family
ID=80975085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210006050.5A Active CN114291821B (en) | 2022-01-05 | 2022-01-05 | PH-responsive copper silicate nanoparticle for enhancing curcumin anti-tumor curative effect and preparation and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114291821B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104888235A (en) * | 2015-05-06 | 2015-09-09 | 中国医学科学院放射医学研究所 | pH sensitive nanoparticles prodrug with capacity of co-delivering multiple drugs, preparation method and application thereof |
| CN107899545A (en) * | 2017-11-28 | 2018-04-13 | 四川大学 | A kind of spherical CSNS Amine nanostructureds CO2The preparation method of adsorbent |
| CN109248325A (en) * | 2018-11-07 | 2019-01-22 | 中国科学院上海硅酸盐研究所 | A kind of low toxicity, efficient oncotherapy nano-medicament carrier material and its preparation method and application |
| CN110101901A (en) * | 2018-02-01 | 2019-08-09 | 中国科学院上海硅酸盐研究所 | Cupric silicate hollow microsphere composite fibrous scaffold and its preparation method and application |
| CN110538329A (en) * | 2019-09-06 | 2019-12-06 | 山西大学 | Preparation method of pH-responsive mesoporous silica nano-drug carrier for three-in-one therapy |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11471542B2 (en) * | 2018-08-06 | 2022-10-18 | Imam Abdulrahman Bin Faisal University | Curcumin-based magnetic nanostructured system for dual response of imaging and therapeutics |
-
2022
- 2022-01-05 CN CN202210006050.5A patent/CN114291821B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104888235A (en) * | 2015-05-06 | 2015-09-09 | 中国医学科学院放射医学研究所 | pH sensitive nanoparticles prodrug with capacity of co-delivering multiple drugs, preparation method and application thereof |
| CN107899545A (en) * | 2017-11-28 | 2018-04-13 | 四川大学 | A kind of spherical CSNS Amine nanostructureds CO2The preparation method of adsorbent |
| CN110101901A (en) * | 2018-02-01 | 2019-08-09 | 中国科学院上海硅酸盐研究所 | Cupric silicate hollow microsphere composite fibrous scaffold and its preparation method and application |
| CN109248325A (en) * | 2018-11-07 | 2019-01-22 | 中国科学院上海硅酸盐研究所 | A kind of low toxicity, efficient oncotherapy nano-medicament carrier material and its preparation method and application |
| CN110538329A (en) * | 2019-09-06 | 2019-12-06 | 山西大学 | Preparation method of pH-responsive mesoporous silica nano-drug carrier for three-in-one therapy |
Non-Patent Citations (1)
| Title |
|---|
| 红细胞膜载药纳米粒子的制备及体外抗肿瘤作用评价;程潜峰等;《中国中药杂志》;20160617(第11期);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114291821A (en) | 2022-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ding et al. | Multifunctional liquid metal-based nanoparticles with glycolysis and mitochondrial metabolism inhibition for tumor photothermal therapy | |
| Osterrieth et al. | Metal–organic framework composites for theragnostics and drug delivery applications | |
| Yu et al. | Perfluorohexane-cored nanodroplets for stimulations-responsive ultrasonography and O2-potentiated photodynamic therapy | |
| CN107349211B (en) | Hollow MnO2Composite nano material, preparation method and application thereof | |
| Geng et al. | Combining anti-PD-1 antibodies with Mn2+-drug coordinated multifunctional nanoparticles for enhanced cancer therapy | |
| Zhang et al. | Therapeutic agent-based infinite coordination polymer nanomedicines for tumor therapy | |
| CN113521098B (en) | Platinum (IV) and cRGD modified GA/Fe nano-particle carried doxorubicin and method for targeted therapy of tumors by using same | |
| Zhang et al. | Engineered anti-cancer nanomedicine for synergistic ferroptosis-immunotherapy | |
| CN112791193A (en) | Application of pH response type copper-based compound nano material as disulfiram carrier in preparation of tumor multi-level selective treatment drug | |
| CN112933052A (en) | Nano drug delivery system for improving tumor hypoxia microenvironment and enhancing immunotherapy | |
| Gu et al. | Dual catalytic cascaded nanoplatform for photo/chemodynamic/starvation synergistic therapy | |
| He et al. | Ultra-dispersed biomimetic nanoplatform fabricated by controlled etching agglomerated MnO2 for enhanced photodynamic therapy and immune activation | |
| Fu et al. | Targeted delivery of Fenton reaction packages and drugs for cancer theranostics | |
| Chi et al. | Dual-Responsive multifunctional “core–shell” magnetic nanoparticles promoting Fenton reaction for tumor ferroptosis therapy | |
| CN110403916B (en) | Nano therapeutic agent and preparation method and application thereof | |
| CN113941009B (en) | Metal organic framework nano-carrier and preparation method and application thereof | |
| Wang et al. | Tunable Zeolitic Imidazolate Framework‐8 Nanoparticles for Biomedical Applications | |
| Zhou et al. | Ovalbumin-modified nanoparticles increase the tumor accumulation by a tumor microenvironment-mediated “giant” | |
| CN114291821B (en) | PH-responsive copper silicate nanoparticle for enhancing curcumin anti-tumor curative effect and preparation and application thereof | |
| Fu et al. | Glucose oxidase and metal catalysts combined tumor synergistic therapy: mechanism, advance and nanodelivery system | |
| CN111773246A (en) | Nano-composite capable of regulating and controlling iron apoptosis and immunotherapy as well as preparation and application thereof | |
| CN110917349A (en) | Bowl-shaped ISP (internet service provider) composite functional nano particle as well as preparation method and application thereof | |
| CN114288418B (en) | Targeting agent-loaded nano composite particle and preparation method and application thereof | |
| CN113827724B (en) | Drug-loaded Prussian blue @ manganese fibrin composite gel, and preparation method and application thereof | |
| CN109276720B (en) | Metal-organic complex nano material and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |